Head to head comparison of <sup>68</sup>Ga-DOTA-FAPI-04 vs <sup>18</sup>F-FDG PET/CT in the evaluation of primary extrapulmonary tumors in the chest.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37668694.
- Also identified by DOI 10.1007/s00330-023-10130-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We conducted a prospective study using <sup>18</sup>F-flurodeoxyglucose (<sup>18</sup>F-FDG) and <sup>68</sup>Ga-DOTA-FAPI-04 (fibroblast-activation protein inhibitor, <sup>68</sup>Ga-FAPI) PET/CT to diagnose, differentiate, and stage primary extrapulmonary tumors of the thorax. Fifty-four participants were undergoing <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI PET/CT and divided into the benign, intermediate, and malignant based on pathology. The maximum standardized uptake value (SUVmax), the tumor-to-blood pool ratio, and tumor-to-liver ratio were compared for primary tumors, lymph nodes, and metastases between the two modalities by two independent samples t tests. One-way ANOVA was used to compare the uptake of <sup>18</sup>F-FDG or <sup>68</sup>Ga-FAPI among the three groups. Fifty-four participants were confirmed to have 71 primary lesions, 56 metastatic lymph nodes, and 43 metastatic lesions. <sup>18</sup>F-FDG PET/CT could both effectively distinguish malignant lesions from non-malignant lesions, accuracies of 87.32% (p < 0.001). <sup>68</sup>Ga-FAPI PET/CT effectively differentiated benign lesions from the non-benign, accuracy being 91.55% (p < 0.001). The accuracies of <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI for detecting lymph node metastasis were 77.22% (61/79) and 87.34% (69/79) (p = 0.096). The uptake of <sup>68</sup>Ga-FAPI in metastatic lymph nodes was significantly higher than that of the nonmetastatic (p < 0.001). The detection rate of <sup>68</sup>Ga-FAPI PET/CT for metastatic lesions was significantly higher than that of <sup>18</sup>F-FDG, 100% (43/43) vs. 53.49% (23/43) (p < 0.001). Compared with <sup>18</sup>F-FDG PET/CT, <sup>68</sup>Ga-FAPI PET/CT changed the treatment strategy of 7.4% (4/54) participants. <sup>68</sup>Ga-FAPI PET/CT is valuable in the diagnosis and differentiation of primary extrapulmonary tumors and superior to <sup>18</sup>F-FDG PET/CT for evaluating lymph node and distant metastasis. The application of <sup>68</sup>Ga-FAPI PET/CT in primary extrapulmonary chest tumors is valuable, which is reflected in diagnosis, differentiation and exploration of lymph node metastasis and distant metastasis. • <sup>68</sup>Ga-FAPI PET/CT is valuable in the diagnosis, differentiation, and staging of primary extrapulmonary tumors. • <sup>68</sup>Ga-FAPI PET/CT is superior to <sup>18</sup> F-FDG PET/CT for evaluating lymph node and distant metastasis.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Liver Neoplasms
- Heterocyclic Compounds, 1-Ring
- Quinolines